Shanghai Bao Pharmaceuticals Co., Ltd., known as BAO PHARMA-B (02659), has released its monthly return for the period ended 28 February 2026. The authorized share capital comprised 154,327,250 H shares and 171,654,215 domestic shares, both having no change from the previous month. Par value for each share remained at RMB 0.2, resulting in an authorized share capital of RMB 30.87 million for H shares and RMB 34.33 million for domestic shares, cumulatively amounting to RMB 65.20 million.

The total number of issued H shares and domestic shares (excluding treasury shares) remained unchanged, at 154,327,250 H shares and 171,654,215 domestic shares, respectively. The announcement also confirmed compliance with the applicable public float requirement, with no movement in treasury shares during the reporting period.